STOCK TITAN

Vivos Therapeutics Q3 2026 net loss narrows to $2M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Vivos Therapeutics, Inc. (VVOS) reported third-quarter 2026 revenue of $6.4 million, up 24% from the second quarter but below $6.8 million a year earlier. Service revenue was $4.6 million, while product revenue was $1.8 million. Gross profit was $3.3 million, and gross margin was 52%, compared with 58% in the prior-year quarter. Operating expenses fell 17% to $7.2 million; operating loss narrowed 18% to $3.9 million. Net loss was $2.0 million versus $5.4 million, including $2.9 million of other income from reversal of the previously recorded Employee Retention Credit liability.

For the first nine months, revenue was $16.7 million versus $13.6 million, while operating loss was $15.3 million versus $13.5 million. At September 30, 2026, cash was $0.2 million, stockholders’ equity was $2.4 million and total liabilities were $20.7 million. During 2026, Vivos exchanged approximately $6.1 million of senior secured debt for equity and said it had eliminated an estimated $5 million or more in annual operating costs. After completing the SOD Sciences transaction on October 16, Nasdaq notified Vivos on October 20 that it had regained compliance with the stockholders’ equity requirement, subject to continued monitoring.

3 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • Moderate pointThird-quarter revenue rose 24% sequentially to $6.4 million.
  • Moderate pointOperating loss improved 18% year over year to $3.9 million.
  • Moderate pointNasdaq stockholders’ equity compliance was regained October 20, subject to continued monitoring.

Negative

  • Moderate pointThird-quarter revenue was $6.4 million, below $6.8 million a year earlier.

Filing Explained

At September thirtieth, cash and equivalents equaled seven point two days of third-quarter operating cash use.

Regaining Nasdaq’s stockholders’ equity compliance did not resolve the separate minimum-bid test: the release warns Vivos may miss the December 2, 2026 deadline, and says a closing bid at or below $0.10 for 10 consecutive business days would trigger a delisting determination and trading suspension without a compliance period.

The release also names failure to obtain stockholder approval of its proposed reverse split as a risk; if approved, a reverse split reduces the share count and proportionally raises the per-share price, without changing company value by itself.

At September 30, 2026, the balance sheet lists 3,610,995 preferred shares issued and outstanding; the release identifies conversion of outstanding preferred stock as a dilution risk. It also reports 33,820,768 common shares outstanding at that date, versus 9,286,609 at December 31, 2025.

Sources and calculations
  • Available liquidity against the last reported quarterly operating outflow, in days at that rate $247,000 / ($3,176,000 / 92) = 7.2 days
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Third-quarter revenue $6.4 million Three months ended September 30, 2026; up 24% from the second quarter and below $6.8 million in the third quarter of 2025.
Third-quarter operating loss $3.9 million Three months ended September 30, 2026; improved 18% from $4.7 million a year earlier.
Third-quarter net loss $2.0 million Three months ended September 30, 2026, compared with $5.4 million a year earlier; includes approximately $2.9 million of other income from reversal of the previously recorded Employee Retention Credit liability.
Third-quarter gross margin 52% Three months ended September 30, 2026, compared with 58% in the third quarter of 2025.
Cash and cash equivalents $0.2 million As of September 30, 2026.
Stockholders’ equity $2.4 million As of September 30, 2026, compared with a $1.5 million stockholders’ deficit as of December 31, 2025.
Senior secured debt exchanged for equity Approximately $6.1 million Exchange completed during 2026.
Estimated annual operating costs eliminated $5 million or more Management’s estimate in the third-quarter update.
gross margin financial
"Gross margin was 52% in the third quarter of 2026"
Gross margin is the difference between how much money a company makes from selling its products and how much it costs to produce them, expressed as a percentage of sales. It shows how efficiently a company is turning sales into profit before other expenses like marketing or salaries. Higher gross margin means the company keeps more money from each sale, which is a good sign of financial health.
Employee Retention Credit liability financial
"reversal of our previously recorded Employee Retention Credit liability"
senior secured debt financial
"approximately $6.1 million of senior secured debt for equity"
Senior secured debt is a loan or bond that has first claim on specific company assets if the company cannot meet its obligations; “senior” means it ranks ahead of other debts and “secured” means it is backed by collateral. Investors care because it usually carries lower risk and lower interest than unsecured debt: in a default holders of senior secured debt are likeliest to recover some money, so this status affects expected returns and safety compared with other claims.
stockholders’ equity requirement regulatory
"regained compliance with Nasdaq’s minimum stockholders’ equity requirement"
A stockholders’ equity requirement is a minimum amount of net assets — assets minus liabilities — that a company must keep on its balance sheet to meet rules set by regulators, lenders or stock exchanges. Think of it as a required safety buffer or minimum bank balance that shows the company has enough of its own capital to absorb losses; falling below it can limit dividends, trigger covenants or risk sanctions, so investors watch it as a sign of financial health and compliance.
EEG testing medical
"including EEG testing and treatment for insomnia"
remote patient monitoring medical
"remote patient monitoring of CPAP users"
Remote patient monitoring is the ongoing collection and transmission of a person’s health data (such as heart rate, blood sugar, or blood pressure) from home or another non-clinical setting to healthcare providers using connected devices and secure networks. For investors, it matters because it can reduce hospital visits, create steady service and device revenue, and change how care is paid for—think of it as a home security system for health that can lower costs and improve outcomes.
Revenue $6.4 million for the third quarter; $16.7 million for the nine months Third-quarter revenue was up 24% from the second quarter and compared with $6.8 million in the third quarter of 2025; nine-month revenue compared with $13.6 million in 2025.
Gross profit $3.3 million for the third quarter; $9.3 million for the nine months Third-quarter gross profit compared with $3.9 million in 2025; nine-month gross profit compared with $7.6 million in 2025.
Gross margin 52% for the third quarter; 56% for the nine months Third-quarter margin compared with 58% in 2025; nine-month margin compared with 55% in 2025.
Operating expenses $7.2 million for the third quarter; $24.7 million for the nine months Third-quarter expenses decreased 17% from $8.7 million; nine-month expenses compared with $21.1 million in 2025.
Operating loss $3.9 million for the third quarter; $15.3 million for the nine months Third-quarter operating loss improved 18% from $4.7 million; nine-month operating loss compared with $13.5 million in 2025.
Net loss $2.0 million for the third quarter; $15.2 million attributable to stockholders for the nine months Third-quarter net loss compared with $5.4 million in 2025; the 2026 quarter included approximately $2.9 million of other income from reversal of the previously recorded Employee Retention Credit liability.
Guidance

Management expects clinical initiatives and payer-contract renegotiations to contribute to revenue and margins beginning in the fourth quarter of 2026 and increasingly throughout 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was VVOS revenue in Q3 2026?

Vivos reported $6.4 million in revenue for the third quarter of 2026, up 24% from $5.2 million in the second quarter and below $6.8 million in the third quarter of 2025.

How much did VVOS lose in Q3 2026?

Vivos reported a $2.0 million net loss for the third quarter of 2026, compared with $5.4 million a year earlier. The 2026 quarter included approximately $2.9 million of other income from reversing its previously recorded Employee Retention Credit liability.

Which clinical initiatives does Vivos expect to contribute to revenue and margins?

Vivos cited EEG testing and treatment for insomnia and other non-OSA sleep disorders, PAP and CPAP treatment distribution and set-up, and remote patient monitoring of CPAP users, alongside payer-contract renegotiations. Management expects contributions beginning in the fourth quarter of 2026 and increasingly throughout 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001716166 0001716166 2026-11-16 2026-11-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 16, 2026

 

VIVOS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-39796   81-3224056

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

7921 Southpark Plaza, Suite 210 Littleton, Colorado   80120
(Address of principal executive offices)   (Zip Code)

 

(866) 908-4867

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value per share   VVOS   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On November 16, 2026, Vivos Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

The information in this Current Report on Form 8-K, including Exhibit 99.1, is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and is not deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press release of the Company, dated November 16, 2026, announcing its financial results for the three and nine months ended September 30, 2026.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  VIVOS THERAPEUTICS, INC.
   
Dated: November 16, 2026 By: /s/ Roman Franklin
  Name: Roman Franklin
  Title: Chief Financial Officer

 

 

 

 

Exhibit 99.1

 

Vivos Therapeutics Reports Third Quarter 2026 Financial Results and Provides Operational Update

 

Revenue rises 24% quarter over quarter as Third quarter operating loss improves 18% year over year on cost reductions; Company regained compliance with Nasdaq stockholders’ equity requirement

 

Management to Host Conference Call today at 5:00 pm ET

 

LITTLETON, Colo., November 16, 2026 – Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea (“OSA”) and other sleep related breathing disorders, today reported financial results and operating highlights for the three and nine months ended September 30, 2026.

 

Kirk Huntsman, Vivos’ Chairman and Chief Executive Officer, stated, “During the third quarter of 2026, we took decisive steps to reduce costs and strengthen our balance sheet. Our operating loss improved 18% compared to the prior-year quarter, general and administrative and sales and marketing expenses together declined by $1.6 million, and we have now eliminated an estimated $5 million or more in annual operating costs, with further efficiencies underway. We also exchanged approximately $6.1 million of senior secured debt for equity during 2026 and, following the closing of our SOD Sciences transaction in October, regained compliance with Nasdaq’s stockholders’ equity requirement.”

 

Mr. Huntsman continued, “We are also pursuing a number of clinical initiatives at our SCN and SAMC centers, including EEG testing and treatment for insomnia and other non-OSA sleep disorders, the distribution and set-up of PAP and CPAP treatments, and remote patient monitoring of CPAP users, together with the renegotiation of our payer contracts. We expect these initiatives to contribute to revenue and margins beginning in the fourth quarter of 2026 and increasingly throughout 2027.”

 

Third Quarter 2026 Financial and Operating Summary

 

 

●

Revenue was $6.4 million for the third quarter of 2026, up 24% from $5.2 million in the second quarter of 2026, and $16.7 million for the nine months ended September 30, 2026, compared to $6.8 million and $13.6 million for the three and nine months ended September 30, 2025. Third quarter service revenue increased 1% to $4.6 million, while product revenue decreased to $1.8 million from $2.2 million, reflecting our strategic pivot away from appliance sales to dentists in our Vivos Integrated Provider (VIP) program. For the nine months, service revenue increased 57% to $12.1 million, primarily attributable to sleep testing and resulting treatment services in our Nevada operations;

     
  ● Gross profit was $3.3 million for the third quarter of 2026 and $9.3 million for the nine months ended September 30, 2026, compared to $3.9 million and $7.6 million for the comparable periods in 2025. The third quarter decrease was due to lower product revenue and higher cost of sales, while the nine-month increase was due to stronger service revenue;
     
  ● Gross margin was 52% in the third quarter of 2026 compared to 58% in the third quarter of 2025, due to the decrease in product revenue. For the nine months ended September 30, 2026, gross margin was 56% compared to 55% in the same period in 2025;
     
  ● Operating expenses for the third quarter ended September 30, 2026 were $7.2 million, a 17% decrease compared to $8.7 million in the same period a year ago, reflecting a $1.4 million reduction in general and administrative expenses, driven primarily by lower professional fees, equipment maintenance and office expenses, as well as lower sales and marketing expenses. For the nine months ended September 30, 2026, operating expenses were $24.7 million versus $21.1 million in the same period in 2025, an increase driven primarily by the costs of establishing our two Sleep and Airway Medicine Centers in Las Vegas and Henderson, Nevada;

 

 
 

 

 

●

The third quarter 2026 operating loss improved 18% to $3.9 million, compared to $4.7 million in the third quarter of 2025. For the nine months ended September 30, 2026, the operating loss was $15.3 million compared to $13.5 million for the nine months ended September 30, 2025.

     
  ● Net loss for the third quarter of 2026 was $2.0 million, compared to $5.4 million in the third quarter of 2025, and included approximately $2.9 million of other income from the reversal of our previously recorded Employee Retention Credit liability;
     
  ● At September 30, 2026, cash and cash equivalents were $0.2 million and total stockholders’ equity was $2.4 million, compared to cash and cash equivalents of $2.0 million and a stockholders’ deficit of $1.5 million as of December 31, 2025. Total liabilities decreased to $20.7 million at September 30, 2026 from $26.7 million at December 31, 2025. Subsequent to quarter end, on October 16, 2026, we completed our SOD Sciences transaction, and on October 20, 2026, Nasdaq notified us that we had regained compliance with its minimum stockholders’ equity requirement, subject to Nasdaq’s continued monitoring.

 

Investor Call and 10-Q Filing

 

Vivos encourages investors and other interested parties to join its conference call today at 5:00 p.m. Eastern time. Management will discuss further details on topics including Vivos’ strategic initiatives and their anticipated effect on near-term revenue growth and cash burn.

 

To access Vivos’ investor conference call, please dial (800) 717-1738, or for international callers, (646) 307-1865. A replay will be available shortly after the call and can be accessed by dialing (844) 512-2921, or for international callers, (412) 317-6671. The Access ID for the replay is 1177865. The replay will be available until Monday, November 30, 2026.

 

A live webcast of the conference call can be accessed on Vivos’ website at https://vivos.com/investor-relations. An online archive of the webcast will be available at Vivos’ website for 30 days following the call.

 

In addition, further information on Vivos’ financial results is included on the attached unaudited condensed consolidated balance sheets and statements of operations, and additional information about Vivos’ financial performance is provided in Vivos’ Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2026, which has been filed with the Securities and Exchange Commission (“SEC”). This press release discusses certain financial information for the second quarter ended June 30, 2026, and more information about our results for the second quarter are included in Vivos’ Quarterly Report on Form 10-Q for the three and six months ended June 30, 2026, which has been filed with the SEC. The full 10-Q reports will be available on the SEC Filings section of the Investor Relations section of Vivos’ website at https://vivos.com/investor-relations.

 

About Vivos Therapeutics, Inc.

 

Vivos Therapeutics, Inc. (Nasdaq: VVOS) is a medical technology and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’ groundbreaking Complete Airway Repositioning and Expansion (CARE) devices were the first oral appliances to receive FDA 510(k) clearance for treating severe OSA in adults and the flagship DNA appliance is the first oral appliance to receive FDA clearance for treating moderate to severe OSA in children.

 

OSA and insomnia affect over 1 billion adults aged 30-69 years old worldwide, yet 80% or more remain undiagnosed and unaware of their condition. These chronic disorders are not just a sleep issue - they are closely linked to many serious chronic health conditions. While the medical community has made strides in treating sleep disorders, breathing and sleep health remain areas that are still not fully understood. As a result, legacy OSA treatments like CPAP are often mechanistic and fail to address the root causes. Vivos CARE oral medical devices target the underlying physiology and anatomical deficiencies that are often associated with OSA.

 

Through innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to address the complex needs of OSA patients more thoroughly.

 

Vivos calls the use of its appliances and protocols to treat OSA The Vivos Method, which offers a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life.

 

For more information, visit www.vivos.com.

 

 
 

 

Cautionary Note Regarding Forward-Looking Statements

 

This press release, the conference call referred to herein, and statements of the Company’s management made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995) concerning future events. Words such as “may”, “should”, “expects”, “projects,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates”, “goal”, “will”, “would”, “could”, “potential”, “continue” and variations of such words and similar expressions are intended to identify forward-looking statements.

 

These statements involve significant known and unknown risks and are based upon a number of assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results (including the actual benefits of the cost reductions, clinical initiatives and other matters described herein and actual revenue and cash flow results) may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to implement revenue, sales and marketing strategies and other strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea treatment sector; (iv) the risk that Vivos may be unable to secure additional financings on reasonable terms when needed, if at all, or maintain its Nasdaq listing due to, among other things, its ability to meet Nasdaq’s stockholders’ equity and minimum bid price requirements; (v) the risk that Vivos will not have enough cash to fund its operations and continue as a going concern; (vi) the risk that the final accounting for the SOD Sciences transaction, or review by Nasdaq or Vivos’ independent registered public accounting firm, results in a smaller increase in stockholders’ equity than expected; (vii) the risk that Vivos will not regain compliance with Nasdaq’s minimum bid price requirement by December 2, 2026 or any extended deadline, or that stockholders will not approve the proposed reverse stock split, or that the closing bid price of Vivos’ common stock will be $0.10 or less for ten consecutive business days, which would result in a Nasdaq delisting determination and suspension of trading without any compliance period; (viii) the risk that the cost reductions described in this press release will not produce the expected savings; (ix) the risk that Vivos’ new clinical initiatives and payer contract renegotiations will not increase revenue or margins when expected, or at all, including because of reimbursement, licensing or other regulatory requirements; (x) dilution from the conversion of outstanding preferred stock; (xi) market and other conditions; and (xii) the other risk factors described in Vivos’ filings with the SEC, including under “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2025 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. Vivos’ filings can be obtained free of charge on the SEC’s website at www.sec.gov.

 

Except to the extent required by law, Vivos expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any such statement is based.

 

Vivos Investor Relations Contact:

 

Jennifer Hauser, Executive Assistant to the CEO

jhauser@vivoslife.com

720-927-3125

 

 
 

 

-Financial Tables Follow-

 

VIVOS THERAPEUTICS INC.

Unaudited Condensed Consolidated Statements of Operations

(In Thousands, Except Per Share Amounts)

 

   Three Months Ended September 30,   Nine Months Ended September 30, 
   2026   2025   2026   2025 
Revenue                    
Product revenue  $1,772   $2,195   $4,567   $5,893 
Service revenue   4,642    4,588    12,141    7,726 
Total revenue   6,414    6,783    16,708    13,619 
                     
Cost of sales (exclusive of depreciation and amortization shown separately below)   3,100    2,846    7,382    6,065 
                     
Gross profit   3,314    3,937    9,326    7,554 
                     
Operating expenses                    
General and administrative   6,450    7,884    22,533    19,181 
Sales and marketing   210    403    614    1,018 
Depreciation and amortization   550    384    1,515    867 
                     
Total operating expenses   7,210    8,671    24,662    21,066 
                     
Operating loss   (3,896)   (4,734)   (15,336)   (13,512)
                     
Non-operating income (expense)                    
Other expense   (981)   (679)   (3,199)   (850)
Other income   2,906    13    3,290    86 
Loss before income taxes   (1,971)   (5,400)   (15,245)   (14,276)
                     
Net loss  $(1,971)  $(5,400)  $(15,245)  $(14,276)
Net loss attributable to non-controlling interest   (26)   -    (137)   - 
Net loss attributable to stockholders  $(1,945)  $(5,400)  $(15,108)  $(14,276)
Net loss per share (basic and diluted)  $(0.07)  $(0.49)  $(0.77)  $(1.49)
Weighted average number of shares of Common Stock outstanding (basic and diluted)   26,528,253    10,963,590    19,658,339    9,557,368 

 

See the notes to the unaudited condensed consolidated financial statements in Vivos’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.

 

 
 

 

VIVOS THERAPEUTICS INC.

Unaudited Condensed Consolidated Balance Sheets

(In Thousands, Except Per Share Amounts)

 

  

September 30,

2026

  

December 31,

2025

 
Current assets          
Cash and cash equivalents  $247   $2,029 
Accounts receivable, net of allowance of $1,250 and $882, respectively   2,370    1,581 
Prepaid expenses and other current assets   891    774 
           
Total current assets   3,508    4,384 
           
Long-term assets          
Goodwill   8,572    8,572 
Property and equipment, net   3,347    3,757 
Operating lease right-of-use asset   3,624    4,166 
Intangible assets, net   3,438    4,045 
Deposits and other   367    228 
           
Total assets  $22,856   $25,152 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY/(DEFICIT)          
Current liabilities          
Accounts payable  $2,739   $1,679 
Accrued expenses   8,819    5,988 
Contract liabilities   72    479 
Current portion of operating lease liability   850    672 
Current portion of financing lease liability   57    55 
Current portion of debt   1,502    8,353 
Other current liabilities   2,124    850 
           
Total current liabilities   16,163    18,076 
           
Long-term liabilities          
Employee retention credit liability   -    2,904 
Operating lease liability, net of current portion   3,198    3,840 
Financing lease liability, net of current portion   69    113 
Debt, net of current portion   313    469 
Other liabilities   950    1,300 
           
Total liabilities   20,693    26,702 
           
Commitments and contingencies   -    - 
           
Stockholders’ equity/(deficit)          
Preferred Stock, $0.0001 par value per share. Authorized 50,000,000 shares; 3,610,995 shares issued and outstanding  $-   $- 
Preferred Stock – additional paid in capital   3,605    - 
Common Stock, $0.0001 par value per share. Authorized 200,000,000 shares; issued and outstanding 33,820,768 shares as of September 30, 2026 and 9,286,609 shares as of December 31, 2025   3    1 
Additional paid-in capital   139,217    123,866 
Accumulated deficit   (140,465)   (125,357)
Total stockholders’ equity/(deficit)   2,360    (1,490)
           
Non-controlling interest   (197)   (60)
Total equity/(deficit)   2,163    (1,550)
           
Total liabilities and equity/(deficit)  $22,856   $25,152 

 

See the notes to the unaudited condensed consolidated financial statements in Vivos’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.

 

 

 

Filing Exhibits & Attachments

4 documents

Keep reading